Skip to main content
. 2022 Apr 28;32(11):7409–7419. doi: 10.1007/s00330-022-08777-5

Table 2.

Results of cost-effectiveness analysis. Results of the base-case cost-effectiveness analysis and of variations of the price per examination of AB-MRI. All values reference a common baseline (XM)

Strategy (cost per examination in US-$) Cumulative discounted costs (US-$) Incremental costs (US-$) Cumulative discounted effects (QALYs) Incremental effects (QALYs) ICER (US-$/QALY)

XM

$ 102

8,718 n/a 19.22 n/a n/a

DBT

$ 214

8,815 97 19.22 0.005 19,785
AB-MRI
$ 314 9,779 1,062 19.25 0.037 28,458
$ 300 9,644 927 19.25 0.037 24,840
$ 280 9,452 734 19.25 0.037 19,671
$ 260 9,259 541 19.25 0.037 14,501
$ 240 9,066 348 19.25 0.037 9,332
$ 220 8,873 155 19.25 0.037 4,163
$ 200 8,680 -38 19.25 0.037 n/a

FB-MRI

$ 314

9,283 565 19.26 0.038 15,018

ICER, incremental cost-effectiveness analysis; QALY, quality-adjusted life year; XM, x-ray mammography; DBT, digital breast tomosynthesis; AB-MRI, abbreviated breast magnetic resonance imaging; FB-MRI, full protocol breast magnetic resonance mammography